Abbott Laboratories (ABT)

Abbott Laboratories Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	46,585	44,328	41,950	40,109	43,653	43,075
Revenue Growth	8.06%	5.67%	4.59%	-8.12%	1.34%	24.46%
Gross Profit Gross Profit Growth	26,482	25,118	23,306	22,190	24,570	24,995
Operating Income Operating Income Growth	8,235	8,917	7,496	7,220	9,113	9,204
Net Income Net Income Growth	5,401	6,500	13,400	5,700	6,905	7,042
Earnings Per Share EPS Growth	3.09	3.72	7.64	3.26	3.91	3.94
EPS Growth	-61.23%	-51.31%	134.36%	-16.62%	-0.76%	57.38%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Established Pharmaceutical Products Established Pharmaceutical Products Growth	5,818	5,536	5,194	5,066	4,912	4,718
Nutritionals Nutritionals Growth	8,254	8,451	8,413	8,154	7,459	8,294
Diagnostics Diagnostics Growth	9,982	8,937	9,341	9,988	16,469	15,526
Medical Devices Medical Devices Growth	22,515	21,387	18,986	16,887	14,802	14,485
Other Segment Other Segment Growth	16	17	16	14	11	52
Revenue (Total) Revenue (Total) Growth	46,585	44,328	41,950	40,109	43,653	43,075

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	5,603	8,939	7,968	7,279	10,170	10,249
Total Debt Total Debt Growth	32,720	14,136	15,326	15,968	17,966	19,251
Net Cash (Debt) Net Cash Growth	-27,117	-5,197	-7,358	-8,689	-7,796	-9,002
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-15.53	-2.97	-4.21	-4.97	-4.42	-5.03

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	9,905	9,566	8,558	7,261	9,581	10,533
Capital Expenditures CapEx Growth	-2,081	-2,171	-2,207	-2,202	-1,777	-1,885
Free Cash Flow Free Cash Flow Growth	7,824	7,395	6,351	5,059	7,804	8,648
Free Cash Flow Growth	15.48%	16.44%	25.54%	-35.17%	-9.76%	51.08%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	56.85%	56.66%	55.56%	55.32%	56.28%	58.03%
Operating Margin	17.68%	20.12%	17.87%	18.00%	20.88%	21.37%
Pretax Margin	16.12%	19.10%	16.72%	16.61%	19.03%	19.06%
Profit Margin	11.59%	14.66%	31.94%	14.21%	15.82%	16.35%
FCF Margin	16.79%	16.68%	15.14%	12.61%	17.88%	20.08%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 17, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	2.520	2.400	2.240	2.080	1.920	1.820
Dividend Per Share Growth	6.90%	7.14%	7.69%	8.33%	5.50%	18.95%
Dividend Yield	2.28%	1.95%	2.05%	2.00%	1.89%	1.42%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 17, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	36.00	33.52	14.64	33.52	27.72	34.28
Forward PE	19.18	22.63	22.39	24.22	26.64	30.05
P/FCF Ratio	24.60	29.46	30.89	37.77	24.53	27.91
PS Ratio	4.13	4.92	4.68	4.76	4.39	5.60

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Aug 13, 2026

Data Sources Report a data error